SEC Company Response from Protara Therapeutics, Inc. (TARA) (CIK 0001359931) (TARA) — Feb 5, 2019
Protara Therapeutics, Inc. (TARA) (CIK 0001359931)
Date: Feb. 5, 2019 · CIK: 0001359931 · Accession: 0001171843-19-000723
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-228865
Letter
Proteon Therapeutics, Inc.
200 West Street
Waltham, MA 02145
(781) 890-0102
February 5, 2019
Via EDGAR and FedEx
United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, NE
Washington, D.C. 20549
Attn: Donald E. Field
RE: Proteon Therapeutics, Inc.
Registration Statement on Form S-3
SEC File No. 333-228865
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Proteon Therapeutics, Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effectiveness of the Company’s above-referenced Registration Statement on Form S-3, as amended, be accelerated to 4:00 p.m. Eastern Time, on February 7, 2019 or as soon as practicable thereafter.
Should you have any questions regarding this request, please do not hesitate to contact Tara R. McElhiney at (713) 890-5732 of Morgan, Lewis & Bockius LLP, counsel to the Company.
Sincerely,
PROTEON THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Proteon Therapeutics, Inc.
200 West Street
Waltham, MA 02145
(781) 890-0102
February 5, 2019
Via EDGAR and FedEx
United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, NE
Washington, D.C. 20549
Attn: Donald E. Field
RE:
Proteon Therapeutics, Inc.
Registration Statement on Form S-3
SEC File No. 333-228865
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Proteon Therapeutics,
Inc., a Delaware corporation (the “Company”), hereby respectfully requests that the effectiveness of the Company’s
above-referenced Registration Statement on Form S-3, as amended, be accelerated to 4:00 p.m. Eastern Time, on February 7, 2019
or as soon as practicable thereafter.
Should you have any questions regarding this request, please do not hesitate to contact
Tara R. McElhiney at (713) 890-5732 of Morgan, Lewis & Bockius LLP, counsel to the Company.
Sincerely,
PROTEON THERAPEUTICS, INC.
/s/ George A. Eldridge
Name: George A. Eldridge
Title: Senior Vice President, Chief Financial
Officer, Treasurer and Assistant Secretary
cc:
Matthew Kowalsky, Proteon Therapeutics, Inc.
Julio E. Vega, Morgan, Lewis & Bockius LLP
Tara R. McElhiney, Morgan, Lewis & Bockius LLP